secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001837607-24-000008
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma closes $5M secured convertible note with Daewoong; 15.79% interest
--------------------------------------------------------------------------------

- Issued $5M senior secured convertible note to Daewoong Pharmaceutical as initial closing of $15M subscription agreement.
- Note accrues interest at 15.79% per annum, matures March 24, 2027.
- Automatically converts at 1.3x principal into shares if AEON raises ≥$30M equity financing at ≥$1.00/share.
- Optional conversion at Daewoong's election upon positive Phase 3 ABP-450 data or change of control.
- Proceeds to fund late-stage clinical development of ABP-450 for migraine and for working capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000183760724000008/0001837607-24-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000183760724000008/aeon-20240324x8k.htm
  HTML page:      https://secwatch.observer/filing/0001837607-24-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer